A detailed history of Qube Research & Technologies LTD transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Qube Research & Technologies LTD holds 96,515 shares of CNTA stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,515
Previous 3,523 2639.57%
Holding current value
$1.65 Million
Previous $31,000 4877.42%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.58 - $16.99 $797,871 - $1.58 Million
92,992 Added 2639.57%
96,515 $1.54 Million
Q2 2024

Aug 14, 2024

SELL
$8.04 - $11.87 $43,584 - $64,347
-5,421 Reduced 60.61%
3,523 $31,000
Q1 2024

May 14, 2024

BUY
$6.73 - $12.2 $51,370 - $93,122
7,633 Added 582.23%
8,944 $101,000
Q4 2023

Feb 13, 2024

BUY
$5.52 - $8.03 $6,855 - $9,973
1,242 Added 1800.0%
1,311 $10,000
Q3 2023

Nov 13, 2023

BUY
$6.01 - $8.24 $414 - $568
69 New
69 $0

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.61B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.